Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study

BACKGROUND: This open-label, phase II study aimed to investigate the efficacy and safety of recombinant human endostatin (Rh-endostatin) plus irinotecan/cisplatin as second-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC). METHODS: Eligible patients received 15mg/m(...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zhihuang, Sun, Si, Zhao, Xinmin, Yu, Hui, Wu, Xianghua, Wang, Jialei, Chang, Jianhua, Wang, Huijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982371/
https://www.ncbi.nlm.nih.gov/pubmed/35380726
http://dx.doi.org/10.1093/oncolo/oyab078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982371/
https://www.ncbi.nlm.nih.gov/pubmed/35380726
http://dx.doi.org/10.1093/oncolo/oyab078

Ejemplares similares